LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Listă Acțiuni・Danaher Corp

Danaher Corp

Închisă

SectorSănătate

171.94 -0.71

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

171.1

Maxim

172.05

Indicatori cheie
By Trading Economics
Venit	-168M 1B
Vânzări	-887M 6B
P/E Medie Sector	31.756 49.701
EPS	2.06
Randament dividend	0.84
Marjă de profit	17.291
Angajați	58,000
EBITDA	-514M 1.5B

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+34.67% upside

Dividende
By Dow Jones
Randament dividend Medie Sector	0.84% 2.39%
Următoarele câștiguri	21 iul. 2026
Data viitoare de dividende	31 iul. 2026
Următoarea dată ex-dividende	26 iun. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-22B 116B
Deschiderea anterioară	172.65
Închiderea anterioară	171.94

Sentimentul știrilor

By Acuity

56%

44%

283 / 345 Clasament în Healthcare

Danaher Corp Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

21 apr. 2026, 11:36 UTC

Câștiguri

Danaher Lifts Full-Year Forecast on Biotech, Life Sciences Gains -- Update

21 apr. 2026, 11:00 UTC

Câștiguri

Danaher Raises Adjusted Earnings Guidance, 1Q Revenue, Profit Rise

21 apr. 2026, 10:06 UTC

Câștiguri

Danaher 1Q Adjsuted Core Revenue Rose 0.5% >DHR

21 apr. 2026, 10:05 UTC

Câștiguri

Danaher Sees 2Q Adjsuted Core Revenue Up Low-Single Digits >DHR

21 apr. 2026, 10:05 UTC

Câștiguri

Danaher Still Sees 2026 Adjsuted Core Revenue Up 3%-6% >DHR

21 apr. 2026, 10:05 UTC

Câștiguri

Danaher Had Seen 2026 Adjusted EPS $8.35-$8.50 >DHR

21 apr. 2026, 10:04 UTC

Câștiguri

Danaher Raises 2026 View To Adj EPS $8.35-Adj EPS $8.55 >DHR

21 apr. 2026, 10:04 UTC

Câștiguri

Danaher 1Q Operating Cash Flow $1.3B, Adjusted Free Cash Flow $1.1B >DHR

21 apr. 2026, 10:00 UTC

Câștiguri

Danaher 1Q Cont Ops EPS $1.45 >DHR

21 apr. 2026, 10:00 UTC

Câștiguri

Danaher 1Q Adj EPS $2.06 >DHR

21 apr. 2026, 10:00 UTC

Câștiguri

Danaher 1Q Sales $5.95B >DHR

21 apr. 2026, 10:00 UTC

Câștiguri

Danaher 1Q EPS $1.45 >DHR

21 apr. 2026, 10:00 UTC

Câștiguri

Danaher 1Q Net $1.03B >DHR

17 apr. 2026, 19:15 UTC

Market Talk

Danaher Seen Rebounding in 2H After Tools-Sector Weakness -- Market Talk

17 apr. 2026, 19:07 UTC

Market Talk

Danaher Faces Tough Comparative but Long‑Term Story Intact -- Market Talk

17 feb. 2026, 20:06 UTC

Achiziții, Fuziuni, Preluări

This Medical-Devices Stock Is Soaring. Danaher Is Buying the Company. -- Barrons.com

17 feb. 2026, 15:14 UTC

Achiziții, Fuziuni, Preluări

Masimo Stock on Pace for Record Gains After Danaher Strikes Deal -- WSJ

17 feb. 2026, 14:39 UTC

Achiziții, Fuziuni, Preluări

This Medical-Devices Stock Is Soaring. It's Being Bought by Danaher. -- Barrons.com

17 feb. 2026, 13:30 UTC

Achiziții, Fuziuni, Preluări

This Medical-Devices Stock Is Soaring. It's Being Bought by Danaher. -- Barrons.com

17 feb. 2026, 13:15 UTC

Achiziții, Fuziuni, Preluări

Danaher Strikes $10 Billion Deal for Masimo -- Update

17 feb. 2026, 13:03 UTC

Achiziții, Fuziuni, Preluări

Danaher To Fund Masimo Acquisition With Cash on Hand, Debt Financing >DHR

17 feb. 2026, 13:03 UTC

Achiziții, Fuziuni, Preluări

Danaher Sees More Than $125M Annual Cost Synergies, More Than $50M Annual Revenue Synergies by Fifth Full Year >DHR MASI

17 feb. 2026, 13:02 UTC

Achiziții, Fuziuni, Preluări

Danaher Sees Masimo Deal Adding About 70c to Adjusted EPS in Fifth Full Year >DHR MASI

17 feb. 2026, 13:02 UTC

Achiziții, Fuziuni, Preluări

Danaher Sees Masimo Deal Adding 15c-20c to Adjusted EPS in First Full Year >DHR MASI

17 feb. 2026, 13:02 UTC

Achiziții, Fuziuni, Preluări

Masimo To Be Acquired By Danaher For $180.00 Per Share >MASI DHR

17 feb. 2026, 13:01 UTC

Achiziții, Fuziuni, Preluări

Danaher to Buy Masimo for Total Enterprise Value of About $9.9 Billion >DHR MASI

17 feb. 2026, 13:00 UTC

Achiziții, Fuziuni, Preluări

Danaher to Buy Masimo for $180/Share >DHR MASI

17 feb. 2026, 13:00 UTC

Achiziții, Fuziuni, Preluări

Danaher To Acquire Masimo Corporation >DHR MASI

17 feb. 2026, 11:09 UTC

Achiziții, Fuziuni, Preluări

Danaher Strikes $10 Billion Deal for Masimo -- WSJ

17 feb. 2026, 11:09 UTC

Achiziții, Fuziuni, Preluări

Danaher Acquisition of Masimo Set to Be Announced Tuesday, Sources Say -- WSJ

Comparație

Modificare preț

Danaher Corp Așteptări

Obiectiv de preț

By TipRanks

34.67% sus

Prognoză pe 12 luni

Medie 231.63 USD 34.67%

Maxim 270 USD

Minim 184.04 USD

În baza a 17 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruDanaher Corp - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

17 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 17 analiști care au acordat evaluări ale acțiunilor Danaher Corp - Dist în ultimele 3 luni.

Sentiment

By Acuity

283 / 345 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Danaher Corp

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.